Migraine Headache, Nausea
Conditions
Interventions
The participants in the metoclopramide arm receive 10 milligrams of metoclopramide intravenously.
The participants in sumatriptan arm receive 3 milligrams of sumatriptan subcutaneously.
Metoclopramide, Sumatriptan
Sponsors
Kimura Akio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Obtained informed consent themselves 2.Age 20-65 years 3.Meeting the criteria for migraine of the ICHD-3beta, except for time duration 4.Moderate to severe intensity of headache
Exclusion criteria
Exclusion criteria: 1. Judged as a high likelihood of secondary headache 2. Temperature over 38.0 degree new objective neurologic abnormality 4.History of myocadiac infarction or suspected of ischemic heart disease 5.History of cerebrovascular disease or transient ischemic attack 6.Peripheral vascular disorder 7.Uncontrolled hypertension or presenting systolic blood pressure over 180mmHg 8.Severe liver dysfunction 9.Suspected of gastrointestinal bleeding, perforation, or obstruction 10.Suspected of pheochromocytoma 11.Use of an ergotamine derivative, other kinds of triptan, MAO inhibitor 12.Pregnant or breast-feeding 13.Allergy to any of the investigational medication 14.Participation judged to be inappropriate by emergency physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in pain score of headaches 1 hour after baseline. The pain score is measured on Numerical Rating Scale for Pain. | — |
Secondary
| Measure | Time frame |
|---|---|
| The change of NRS 30 minutes after medications Headache relief 1 hour after medications, defined as the patient's description of headache from severe or moderate to either mild or none Concomitant symptoms at the time of 1 hour after medication Time duration from study medication to leaving the ED Receipt of rescue medication during the ED visit Adverse events | — |
Contacts
Public ContactYumi Funato
National Center for Global Health and Medicine
Outcome results
None listed